DEPARTMENT OF HEALTH & HUMAN SERVICES



Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland 20852

Telephone: 240-453-8132 FAX: 240-453-6909 E-mail:kborror@osophs.dhhs.gov

May 23, 2006

Roberto Peccei, Ph.D. Vice Chancellor - Research University of California, Los Angeles 2147 Murphy Hall, Box 951405 Los Angeles, CA 90095-1405

RE: Human Research Subject Protections Under Multiple Project Assurance (MPA)-1127 and Federalwide Assurance FWA- 4642

<u>Research Project</u>: Protocol TSVS-701-25G: A Prospective, Non-Randomized, Multicenter Clinical Evaluation of the 25-Gauge Millennium TM Transconjuctival Sutureless Vitrectomy System (TSVS) with Entry Site Alignment System (ESAS) <u>Principal Investigator</u>: Steven Schwartz, M.D. UCLA IRB #: 01-11-057-01

<u>Research Project</u>: 25-Gauge Vitrectomy System Registry <u>Principal Investigator</u>: Anurag Gupta, M.D. <u>UCLA IRB #</u>: 04-07-004

<u>Research Project</u>: Clinical Characterization, Genetic Testing, and Visual Function in Patients with Stargardt's Disease <u>Principal Investigator</u>: Steven Nusinowitz, Ph.D. <u>UCLA IRB #</u>: 04-10-010

<u>Research Project</u>: Genetic Studies in Inherited Ocular Disorders <u>Principal Investigator</u>: Anthony Aldave, M.D. <u>UCLA IRB #</u>: 94-07-243-23

<u>Research Project</u>: Research on intra-ocular pressure of patients receiving Bausch and Lomb 25-Gauge Trocar System <u>Principal Investigator</u>: Steven Schwartz, M.D., Anu Gupta, M.D., and Christine Gonzalez, M.D. Page 2 of 2 Roberto Peccei, Ph.D.– University of California, Los Angeles May 23, 2006

Dear Dr. Peccei:

The Office for Human Research Protections (OHRP) has reviewed the University of California, Los Angeles's (UCLA) April 17, 2006 report responding to determinations of noncompliance with Department of Health and Human Services (HHS) regulations for the protection of human research subjects (45 CFR part 46) involving the above-referenced research.

Based upon its review, OHRP finds that your responses and corrective actions adequately address OHRP's findings, questions and concerns and are appropriate under the UCLA FWA. As a result, OHRP anticipates no further involvement in this matter.

OHRP appreciates the continued commitment of your institution to the protection of human research subjects. Please do not hesitate to contact me should you have any questions.

Sincerely,

Kristina C. Borror, Ph.D. Director Division of Compliance Oversight

cc: Ms. Judith L. Brookshire, Director, OPRS, UCLA Dr. Lawrence E. Wolinsky, IRB Chair, General Biomedical IRB #1, UCLA Dr. Robert A. Figlin, IRB Chair, Cancer/Infec Dis IRB #2, UCLA Dr. Nancy Levine, IRB Chair, North General Social-Behav IRB#3, UCLA Dr. Bruce Kagan, IRB Chair, Neuroscience IRB #4, UCLA Dr. Alison Moore, IRB Chair, South General IRB #5, UCLA Dr. Steven Schwartz, UCLA Commissioner, FDA Dr. David Lepay, FDA Dr. Bernard Schwetz, OHRP Dr. Melody H. Lin, OHRP Dr. Michael Carome, OHRP Ms. Shirley Hicks, OHRP Dr. Irene Stith-Coleman, OHRP Ms. Janet Fant, OHRP Ms. Patricia El-Hinnawy, OHRP